SIEN - Sientra, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.70
+0.25 (+2.96%)
As of 1:49PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close 8.45
Open 8.45
Bid 8.70 x 800
Ask 8.72 x 800
Day's Range 8.33 - 8.81
52 Week Range 7.10 - 26.79
Volume 308,458
Avg. Volume 866,266
Market Cap 254.144M
Beta (3Y Monthly) 1.40
PE Ratio (TTM) N/A
EPS (TTM) -3.25
Earnings Date May 8, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 19.38
Trade prices are not sourced from all markets
  • Here's Why Sientra's Shares Got a Lift Today
    Motley Fool 2 days ago

    Here's Why Sientra's Shares Got a Lift Today

    The FDA approved a design change for the company's Opus breast implants.

  • GlobeNewswire 6 days ago

    Sientra to Release First Quarter Financial Results on May 8, 2019

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra” or the “Company”), announced today that the Company will release its first quarter 2019 financial results on Wednesday, May 8, 2019 after market close. Sientra will hold a conference call on Wednesday, May 8, 2019 at 4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 4:00 p.m. ET that same day.

  • Those Who Purchased Sientra (NASDAQ:SIEN) Shares A Year Ago Have A 32% Loss To Show For It
    Simply Wall St. 7 days ago

    Those Who Purchased Sientra (NASDAQ:SIEN) Shares A Year Ago Have A 32% Loss To Show For It

    It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners, plenty more fail to generate satisfactory returns. That downside risk was realized by Sientra, Inc. (NASDAQ:SIE...

  • GlobeNewswire last month

    Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra" or the “Company”), today announced it has provided an initial response to the U.S. Food and Drug Administration (“FDA”) related to a post-approval study Warning Letter issued on March 19, 2019 and will provide a comprehensive plan for compliance to FDA within 15 days.

  • Reuters last month

    J&J and Sientra get FDA warning letters over breast implants

    The U.S. Food and Drug Administration has issued warning letters to Sientra Inc and a Johnson & Johnson unit for failing to comply with the post-approval study requirements for their breast implants. Last month, the FDA issued a statement https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm630863.htm warning doctors about a type of lymphoma linked to breast implants after receiving reports of the disease. The agency's letters http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190319:nPn7rwbQSa, dated March 18, highlighted issues in the companies' post-approval studies, which included evaluating the long-term performance and safety of the implants, used for breast augmentation and reconstruction procedures.

  • Read This Before Selling Sientra, Inc. (NASDAQ:SIEN) Shares
    Simply Wall St. last month

    Read This Before Selling Sientra, Inc. (NASDAQ:SIEN) Shares

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • Thomson Reuters StreetEvents last month

    Edited Transcript of SIEN earnings conference call or presentation 12-Mar-19 8:30pm GMT

    Q4 2018 Sientra Inc Earnings Call

  • Associated Press last month

    Vera Bradley and Guardant Health surge while Express falls

    Stocks that moved substantially or traded heavily on Wednesday: Rite Aid Corp., up 4 cents to 72 cents The drugstore chain purged its top management, including CEO John Stanley, and said it will cut 400 ...

  • Here's Why Sientra Stock Is Plummeting Today
    Motley Fool last month

    Here's Why Sientra Stock Is Plummeting Today

    Investors are worried about the aesthetics company's profitability.

  • TheStreet.com last month

    Sientra Plunges After Posting Wider-Than-Expected Loss

    , a plastic surgery product maker, were falling hard Wednesday after the company reported a wider-than-expected fourth-quarter loss. Sientra lost 87 cents a share in the quarter, wider than analysts' calls for a loss of 67 cents. The company has missed earnings estimates in the last four quarters.

  • Sientra Inc (SIEN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool last month

    Sientra Inc (SIEN) Q4 2018 Earnings Conference Call Transcript

    SIEN earnings call for the period ending December 31, 2018.

  • Sientra (SIEN) Reports Q4 Loss, Tops Revenue Estimates
    Zacks last month

    Sientra (SIEN) Reports Q4 Loss, Tops Revenue Estimates

    Sientra (SIEN) delivered earnings and revenue surprises of -28.36% and 0.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press last month

    Sientra: 4Q Earnings Snapshot

    The Santa Barbara, California-based company said it had a loss of 86 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire last month

    Sientra Reports Fourth Quarter and Full Year 2018 Financial Results

    Fourth Quarter 2018 Net Sales of $19.0 Million, Growth of 72% YoY on a GAAP Basis 2018 Net Sales of $68.1 Million, Growth of 86% YoY on a GAAP Basis and 46% YoY Pro Forma.

  • ACCESSWIRE last month

    Sientra, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Sientra, Inc. (NASDAQ: SIEN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 12, 2019, 2018 at 4:30 PM ...

  • GlobeNewswire 2 months ago

    Sientra® to Release Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

    Sientra, Inc. (SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its fourth quarter and full year 2018 financial results on Tuesday, March 12, 2019 after market close. Sientra will hold a conference call on Tuesday, March 12, 2019 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. A press release disclosing the Company's financial results will be distributed at approximately 1:00 p.m. PT/4:00 p.m. ET that same day.

  • GlobeNewswire 2 months ago

    Market Trends Toward New Normal in Micron Technology, Harris, Sientra, Noble, Amphastar Pharmaceuticals, and CECO Environmental — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire 2 months ago

    Sientra to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SANTA BARBARA, Calif., Feb. 19, 2019 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, announced today that members of management are scheduled to present at the.

  • What You Must Know About Sientra, Inc.’s (NASDAQ:SIEN) Financial Strength
    Simply Wall St. 2 months ago

    What You Must Know About Sientra, Inc.’s (NASDAQ:SIEN) Financial Strength

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth inRead More...

  • GlobeNewswire 3 months ago

    Sientra Announces miraDry Leadership Transition

    Sientra, Inc. (SIEN), a medical aesthetics company, announced today that it has appointed Kirk Gunhus to the position of General Manager of miraDry, effective immediately. Mr. Gunhus succeeds Patrick Williams, who is leaving Sientra.

  • GlobeNewswire 3 months ago

    Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that on January 31, 2019, the Compensation Committee of the Board of Directors approved equity award grants under the Sientra Inc. Inducement Plan to 39 new employees. The new employees were granted restricted stock units representing a total of 80,561 shares of common stock. The restricted stock units will vest in time-based installments beginning on the grant date.  In each case, the vesting of shares is contingent upon the recipient’s continued service with the Company through each vesting date.

  • GlobeNewswire 4 months ago

    Sientra Announces Preliminary Unaudited Fourth Quarter 2018 Net Sales and Appointment of Aesthetic Industry Veteran to Board of Directors

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced preliminary unaudited nets sales for the fourth quarter 2018. In addition, as previously disclosed, the Board of Directors of Sientra appointed Mary M. Fisher as a director of the Company effective January 1, 2019.

  • Is Sientra Inc (SIEN) A Good Stock To Buy?
    Insider Monkey 4 months ago

    Is Sientra Inc (SIEN) A Good Stock To Buy?

    “October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Simply Wall St. 4 months ago

    How Much Did Sientra, Inc.’s (NASDAQ:SIEN) CEO Pocket Last Year?

    In 2015 Jeff Nugent was appointed CEO of Sientra, Inc. (NASDAQ:SIEN). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look Read More...